Open AccessPopulation Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients
Author(s) -
Michael Trang,
David C. Griffith,
Sujata M. Bhavnani,
Jeffery S. Loutit,
Michael N. Dudley,
Paul G. Ambrose,
Christopher M. Rubino
Publication year - 2021
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02606-20
Subject(s) - pharmacokinetics , medicine , volume of distribution , nonmem , meropenem , renal function , population , pharmacodynamics , clearance , covariate , urinary system , antibiotics , pharmacology , urology , biology , microbiology and biotechnology , antibiotic resistance , statistics , mathematics , environmental health
Meropenem-vaborbactam is a broad-spectrum carbapenem–beta-lactamase inhibitor combination approved in the United States and Europe to treat patients with complicated urinary tract infections and in Europe for other serious bacterial infections, including hospital-acquired and ventilator-associated pneumonia. Population pharmacokinetic (PK) models were developed to characterize the time course of meropenem and vaborbactam using pooled data from two phase 1 and two phase 3 studies.